MenoGeniX is a privately held clinical stage biopharmaceutical company, dedicated to researching and developing a novel treatment that seeks to provide relief to women suffering from hot flashes and related vasomotor symptoms of menopause.
Located in Aurora Colorado, adjacent to the University of Colorado School of Medicine, MenoGeniX began operations in 2012 and filed a series of U.S. and international patent applications. Patents have issued in the United States, Australia, China and Japan. Other foreign patents are anticipated to issue in 2017.
MenoGeniX completed a Phase Ib clinical trial to investigate the effectiveness of MNGX-100 for treating hot flashes in women with naturally occurring and surgically induced menopausal hot flashes. The trial produced positive results, informing the design for a larger Phase IIb/III trial.